Marshall Wace LLP trimmed its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 42.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,967 shares of the biotechnology company’s stock after selling 4,439 shares during the quarter. Marshall Wace LLP’s holdings in Sarepta Therapeutics were worth $711,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter worth about $35,000. Quad Cities Investment Group LLC increased its holdings in shares of Sarepta Therapeutics by 100.0% in the first quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 200 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Sarepta Therapeutics in the first quarter worth about $51,000. Manchester Capital Management LLC bought a new stake in Sarepta Therapeutics during the first quarter worth approximately $68,000. Finally, First Manhattan Co. bought a new stake in Sarepta Therapeutics during the first quarter worth approximately $107,000. 94.36% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics stock traded down $2.37 during mid-day trading on Friday, reaching $149.26. 1,273,155 shares of the company were exchanged, compared to its average volume of 1,486,694. The firm’s fifty day moving average is $136.32. The company has a debt-to-equity ratio of 0.35, a quick ratio of 11.15 and a current ratio of 12.17. The firm has a market cap of $11.24 billion, a price-to-earnings ratio of -27.34 and a beta of 2.12. Sarepta Therapeutics Inc has a 12-month low of $95.21 and a 12-month high of $165.87.
In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total value of $1,200,000.00. Following the transaction, the director now directly owns 21,717 shares of the company’s stock, valued at approximately $2,606,040. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.60% of the stock is owned by corporate insiders.
SRPT has been the topic of several analyst reports. ValuEngine cut WideOpenWest from a “hold” rating to a “sell” rating in a research note on Friday, June 28th. Citigroup set a $6.00 price objective on Solid Biosciences and gave the stock a “hold” rating in a research note on Thursday, May 16th. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Monday, June 17th. Evercore ISI began coverage on Homology Medicines in a research note on Thursday, April 11th. They set an “outperform” rating and a $29.00 target price on the stock. Finally, Royal Bank of Canada cut Roku from an “outperform” rating to a “sector perform” rating and set a $90.00 target price on the stock. in a research note on Monday, July 1st. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $206.82.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.